Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 707 clinical trials
Featured trial
Venous Thromboembolism in Primary Pancreatic Tumour Resection (PaTR-VTE)

This study will evaluate the development of venous thromboembolism (VTE) and possible determinants in patients with primary pancreatic cancer undergoing pancreatic cancer resection.

  • 0 views
  • 24 Nov, 2025
Featured trial
Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma

This project will evaluate the efficacy and safety of the conditioning regimen bortezomib-bendamustine-melphalan (BBM) in combination with autologous hematopoietic stem cell transplantation (ASCT) in relapsed multiple myeloma given from 2011 to 2018 at Uppsala University Hospital. This approach will be retrospectively compared to high dose melphalan (HDM) in the same …

  • 0 views
  • 01 Dec, 2025
  • 2 locations
A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707)  

ul>

  • 0 views
  • 04 Apr, 2025
  • 1 location
  • Online study
SAR408701 Versus Docetaxel in Previously Treated Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients  

  • The primary objective is to determine whether SAR408701 improves the overall survival (OS) when compared with docetaxel in participants with metastatic non-squamous NSCLC expressing CEACAM5 2+ in intensity in at least 50% of the tumor cell population and previously treated with standard-of-care platinum-based chemotherapy and an immune checkpoint inhibitor.
    • ul>

    …

    cancer
    measurable disease
    small cell lung cancer
    docetaxel
    stage iv non-small cell lung cancer
    • 0 views
    • 19 Feb, 2024
    • 55 locations
    A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

    Eligible participants will be randomized in a 1:1 ratio to receive one of the following treatment regimens during induction phase:-

    <ul>
  • Arm A: Tiragolumab plus atezolizumab and CE
  • Arm B: Placebo plus atezolizumab and CE
    • ul>

    Following the induction phase, participants will continue maintenance therapy with either atezolizumab …

    cancer
    solid tumour
    measurable disease
    small cell lung cancer
    extensive stage sclc
    • 0 views
    • 19 Feb, 2024
    • 147 locations
    Determination of the Optimal Treatment Target in Ulcerative Colitis

    Participants with active UC will be randomized in a 2:3:5 ratio to 1 of 3 groups, each with a different treatment target. Treatment targets will be defined as:

    <ul>
  • Group 1: corticosteroid-free symptomatic remission
  • Group 2: corticosteroid-free endoscopic + symptomatic remission
  • Group 3: corticosteroid-free histological + endoscopic …

    corticosteroids
    ulcerative colitis
    tuberculosis
    hematochezia
    colitis
    • 0 views
    • 19 Feb, 2024
    • 1 location
    Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (AIRLYMPUS)

  • The investigational treatment duration will be up to approximately 52 weeks.
  • The number of visits will be 18.
    • ul>

    • 0 views
    • 24 Nov, 2025
    • 51 locations
    A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

    ul>

    b-cell lymphoma
    alkylating agents
    fludarabine
    marginal zone lymphoma
    follicular lymphoma
    • 0 views
    • 19 Feb, 2024
    • 36 locations
    SAR439859 Plus Palbociclib as First Line Therapy for Patients With ER(+) HER2(-) Advanced Breast Cancer

    Primary Objective:

    To determine whether SAR439859 in combination with palbociclib improves progression free survival (PFS) when compared with letrozole in combination with palbociclib in participants with ER+, HER2- advanced breast cancer who have not received any prior systemic anticancer therapies for advanced disease.

    Secondary Objective:

    <ul>
  • To compare …

    her2-negative breast cancer
    cancer
    measurable disease
    solid tumour
    HER2
    • 0 views
    • 19 Feb, 2024
    • 5 locations
    Phase 2 Study of SAR439859 Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)

  • To compare the overall safety profile in the 2 treatment arms.
    • ul>

    cancer
    cancer metastatic
    immunological adjuvant
    estrogen
    breast cancer
    • 0 views
    • 19 Feb, 2024
    • 131 locations